Publications on AMPA Receptors and the Development of AMPA Receptor Antagonists for the Treatment of Epilepsy
Donevan SD, Rogawski MA. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron. 1993 Jan;10(1):51-9. PubMed PMID: 7678966.
Yamaguchi S, Donevan SD, Rogawski MA. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 1993 Jul;15(3):179-84. PubMed PMID: 7693450.
Rogawski MA. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci. 1993 Sep;14(9):325-31. Review. PubMed PMID: 7504360.
Donevan SD, Yamaguchi S, Rogawski MA. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity. J Pharmacol Exp Ther. 1994 Oct;271(1):25-9. PubMed PMID: 7525924.
Donevan SD, Rogawski MA. Intracellular polyamines mediate inward rectification of Ca2+-permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9298-302. PubMed PMID: 7568121; PubMed Central PMCID: PMC40972.
Rogawski MA. Excitatory amino acids and seizures. In, CNS Neurotransmitters and Neuromodulators, Volume 1: Glutamate (T.W. Stone, ed.), CRC Press, Boca Raton, 1995;219–237.
Rogawski MA. Epilepsy. In, Neurotherapeutics: Emerging Strategies (Pullan L, Patel J, eds.), Humana Press, Totowa, NJ, 1996;193–273.
Donevan SD, Rogawski MA. Allosteric regulation of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors by thiocyanate and cyclothiazide at a common modulatory site distinct from that of 2,3-benzodiazepines. Neuroscience. 1998 Dec;87(3):615-29. PubMed PMID: 9758228.
Rogawski MA, Donevan SD. AMPA receptors in epilepsy and as targets for antiepileptic drugs. In, Jasper’s Basic Mechanisms of the Epilepsies (A.V. Delgado-Escueta, W.A. Wilson, R.W. Olsen and R.J. Porter, eds.), Lippincott Williams & Wilkins, Philadelphia, 1999; 947–963.
Rogawski MA, Kurzman PS, Yamaguchi SI, Li H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology. 2001;40(1):28-35. PubMed PMID: 11077068.
Witkin JM, Kaminski R, Rogawski MA. Pharmacology of glutamate receptors. In, Contemporary Clinical Neuroscience: Glutamate and Addiction (Herman BH, Frankenheim J, Litten RZ, Sheridan PH, WeightFF, Zukin SR, eds.), Humana Press, Totowa, NJ, 2002;23–49.
Löscher W, Rogawski MA. Epilepsy. In, Ionotropic Glutamate Receptors as Therapeutic Targets (D. Lodge, W. Danysz and C.G. Parsons, eds.), F.P. Graham Publishing Co., Johnson City, TN, 2002;91–132.
Gryder DS, Castaneda DC, Rogawski MA. Evidence for low GluR2 AMPA receptor subunit expression at synapses in the rat basolateral amygdala. J Neurochem. 2005 Sep;94(6):1728-38. Epub 2005 Jul 25. PubMed PMID: 16045445; PubMed Central PMCID: PMC1352164.
Fritsch B, Stott JJ, Joelle Donofrio J, Rogawski MA. Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. Epilepsia. 2010 Jan;51(1):108-17. doi: 10.1111/j.1528-1167.2009.02205.x. Epub 2009 Jul 20. PubMed PMID: 19682025.
Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011 Mar;11(2):56-63. doi: 10.5698/1535-7511-11.2.56. PubMed PMID: 21686307; PubMed Central PMCID: PMC3117497.
French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012 Aug 7;79(6):589-96. doi: 10.1212/WNL.0b013e3182635735. Epub 2012 Jul 25. PubMed PMID: 22843280; PubMed Central PMCID: PMC3413761.
Rogawski MA. AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl. 2013;(197):9-18. doi: 10.1111/ane.12099. Review. PubMed PMID: 23480151.
Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;(197):19-24. doi: 10.1111/ane.12100. Review. PubMed PMID: 23480152.
Chen CY, Matt L, Hell JW, Rogawski MA. Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons. PLoS One. 2014 Sep 17;9(9):e108021. doi: 10.1371/journal.pone.0108021. eCollection 2014. PubMed PMID: 25229608.
Rogawski MA, Yang H, Fant R, Williams B, Ma T, Dobrinsky C, Laurenza A. Perampanel discontinuation Is not associated with self-reported withdrawal symptoms. American Epilepsy Society 2014 Annual Meeting. Also presented at the 2015 Annual Meeting of the American Academy of Neurology; poster is available here.
Donevan SD, Rogawski MA. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron. 1993 Jan;10(1):51-9. PubMed PMID: 7678966.
Yamaguchi S, Donevan SD, Rogawski MA. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 1993 Jul;15(3):179-84. PubMed PMID: 7693450.
Rogawski MA. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci. 1993 Sep;14(9):325-31. Review. PubMed PMID: 7504360.
Donevan SD, Yamaguchi S, Rogawski MA. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity. J Pharmacol Exp Ther. 1994 Oct;271(1):25-9. PubMed PMID: 7525924.
Donevan SD, Rogawski MA. Intracellular polyamines mediate inward rectification of Ca2+-permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9298-302. PubMed PMID: 7568121; PubMed Central PMCID: PMC40972.
Rogawski MA. Excitatory amino acids and seizures. In, CNS Neurotransmitters and Neuromodulators, Volume 1: Glutamate (T.W. Stone, ed.), CRC Press, Boca Raton, 1995;219–237.
Rogawski MA. Epilepsy. In, Neurotherapeutics: Emerging Strategies (Pullan L, Patel J, eds.), Humana Press, Totowa, NJ, 1996;193–273.
Donevan SD, Rogawski MA. Allosteric regulation of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors by thiocyanate and cyclothiazide at a common modulatory site distinct from that of 2,3-benzodiazepines. Neuroscience. 1998 Dec;87(3):615-29. PubMed PMID: 9758228.
Rogawski MA, Donevan SD. AMPA receptors in epilepsy and as targets for antiepileptic drugs. In, Jasper’s Basic Mechanisms of the Epilepsies (A.V. Delgado-Escueta, W.A. Wilson, R.W. Olsen and R.J. Porter, eds.), Lippincott Williams & Wilkins, Philadelphia, 1999; 947–963.
Rogawski MA, Kurzman PS, Yamaguchi SI, Li H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology. 2001;40(1):28-35. PubMed PMID: 11077068.
Witkin JM, Kaminski R, Rogawski MA. Pharmacology of glutamate receptors. In, Contemporary Clinical Neuroscience: Glutamate and Addiction (Herman BH, Frankenheim J, Litten RZ, Sheridan PH, WeightFF, Zukin SR, eds.), Humana Press, Totowa, NJ, 2002;23–49.
Löscher W, Rogawski MA. Epilepsy. In, Ionotropic Glutamate Receptors as Therapeutic Targets (D. Lodge, W. Danysz and C.G. Parsons, eds.), F.P. Graham Publishing Co., Johnson City, TN, 2002;91–132.
Gryder DS, Castaneda DC, Rogawski MA. Evidence for low GluR2 AMPA receptor subunit expression at synapses in the rat basolateral amygdala. J Neurochem. 2005 Sep;94(6):1728-38. Epub 2005 Jul 25. PubMed PMID: 16045445; PubMed Central PMCID: PMC1352164.
Fritsch B, Stott JJ, Joelle Donofrio J, Rogawski MA. Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. Epilepsia. 2010 Jan;51(1):108-17. doi: 10.1111/j.1528-1167.2009.02205.x. Epub 2009 Jul 20. PubMed PMID: 19682025.
Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011 Mar;11(2):56-63. doi: 10.5698/1535-7511-11.2.56. PubMed PMID: 21686307; PubMed Central PMCID: PMC3117497.
French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012 Aug 7;79(6):589-96. doi: 10.1212/WNL.0b013e3182635735. Epub 2012 Jul 25. PubMed PMID: 22843280; PubMed Central PMCID: PMC3413761.
Rogawski MA. AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl. 2013;(197):9-18. doi: 10.1111/ane.12099. Review. PubMed PMID: 23480151.
Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;(197):19-24. doi: 10.1111/ane.12100. Review. PubMed PMID: 23480152.
Chen CY, Matt L, Hell JW, Rogawski MA. Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons. PLoS One. 2014 Sep 17;9(9):e108021. doi: 10.1371/journal.pone.0108021. eCollection 2014. PubMed PMID: 25229608.
Rogawski MA, Yang H, Fant R, Williams B, Ma T, Dobrinsky C, Laurenza A. Perampanel discontinuation Is not associated with self-reported withdrawal symptoms. American Epilepsy Society 2014 Annual Meeting. Also presented at the 2015 Annual Meeting of the American Academy of Neurology; poster is available here.